Athersys, Inc. (ATHX) News

Athersys, Inc. (ATHX): $1.89

-0.30 (-13.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATHX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 384

in industry

Filter ATHX News Items

ATHX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ATHX News Highlights

  • For ATHX, its 30 day story count is now at 3.
  • Over the past 11 days, the trend for ATHX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • MAIA and MAYS are the most mentioned tickers in articles about ATHX.

Latest ATHX News From Around the Web

Below are the latest news stories about ATHERSYS INC that investors may wish to consider to help them evaluate ATHX as an investment opportunity.

Athersys to Host Business Update Conference Call on October 6th

CLEVELAND, September 30, 2022--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert "Willie" Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will pro

Yahoo | September 30, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're breaking down the biggest pre-market stock movers for Friday morning alongside the news that traders need to know about!

William White on InvestorPlace | September 23, 2022

Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering

CLEVELAND, September 23, 2022--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it has entered into amended agreements to extend the exercise period of the warrants that were issued as part of a registered direct offering that closed on August 17, 2022, among other changes, and to issue additional warrants to the same warrant holder, a healthcare-focused U.S. institutional investor.

Yahoo | September 23, 2022

The Three Best Anti-Aging Stocks to Buy in September

Innovative medical technology companies and anti-aging stocks are the subject of much interest on Wall Street

Tezcan Gecgil on InvestorPlace | September 19, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're breaking down the biggest pre-market stock movers and the news that has them rising and falling for Monday morning!

William White on InvestorPlace | August 29, 2022

Athersys Announces 1-for-25 Reverse Stock Split

CLEVELAND, August 25, 2022--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 after the close of trading on the Nasdaq Stock Market on Friday, August 26, 2022. Athersys common stock will begin trading on a split-adjusted basis when the market opens on Monday, August 29, 2022 under the exi

Yahoo | August 25, 2022

Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering

CLEVELAND, August 17, 2022--Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced registered direct offering with a single healthcare-focused U.S. institutional investor for the purchase of 48,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 48,000,000 shares of common stock at a combined purchase price of $0.25, resulting in gross proceeds of approximately $12 million before deducting placem

Yahoo | August 17, 2022

Athersys, Inc. Announces $12 Million Registered Direct Offering

CLEVELAND, August 15, 2022--Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 48,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 48,000,000 shares of common stock at a purchase price per share (and accompanying warrant) of $0.25 in a registered direct offering. The warrants will have an exer

Yahoo | August 15, 2022

News Flash: One Analyst Just Made An Incredible Upgrade To Their Athersys, Inc. (NASDAQ:ATHX) Forecasts

Shareholders in Athersys, Inc. ( NASDAQ:ATHX ) may be thrilled to learn that the covering analyst has just delivered a...

Yahoo | August 14, 2022

Athersys (ATHX) Q2 2022 Earnings Call Transcript

Please note that any remarks that management may make about future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by the forward-looking statements as a result of various factors, including those discussed in our Forms 10-Q, 10-K and other SEC filings. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

Yahoo | August 12, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6078 seconds.